N/A
N=15
Testing of Computer Aided Detection Software for Riverain Medical Group
Lung Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00906789 ↗Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: Improvement in Cancer Detection as Measured by Localized Receiver Operating Characteristic) LROC Changes Under the LROC Curve. — 0.460; 0.558 unitless — p=0.05
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Software (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- Georgetown University
- Primary completion
- Jun 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Improvement in Cancer Detection as Measured by Localized Receiver Operating Characteristic) LROC Changes Under the LROC Curve. |
0.460; 0.558 | 0.05 |
| SECONDARY Sensitivity and Specificity Using SoftView Software |
49.5; 66.3; 96.1; 91.8 | — |
Summary
This is a clinical trial using retrospective data of two different software devices developed by Riverain Medical Group: Softview and OnGuard 5.0. The two studies will be run concurrently. Riverain Medical Group's computer systems are designed to assist radiologists in their identification of lung cancer on chest radiographs. The current machine received FDA Pre-Market Approval. This is to test two new software approaches.
Eligibility Criteria
Inclusion Criteria
- US American Board of Radiology Certified Radiologists in active clinical practice
Exclusion Criteria
- Specialists in pulmonary or chest or cardio-pulmonary radiology Prior membership on expert panels for this study who prepared cases Current or recent colleagues or trainees (within 10 years) of the Principal Investigator
Data sourced from ClinicalTrials.gov (NCT00906789). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.